The US Food and Drug Administration (FDA) has approved Autolus Therapeutics’ Aucatzyl (obecabtagene autoleucel) to treat ...

Daiichi Sankyo has entered into an exclusive licence agreement worth up to $300m with Alteogen to develop a subcutaneous version of its AstraZeneca-partnered antibody-drug conjugate (ADC) Enhertu (fam ...

The National Institute for Health and Care Excellence (NICE) has recommended Blueprint Medicines’ Ayvakyt (avapritinib) to treat patients with the rare blood disorder systemic mastocytosis (SM). The ...

A UK study has demonstrated that interventions to reduce respiratory syncytial virus (RSV) infections could help to reduce antibiotic prescribing and therefore antimicrobial resistance (AMR), which is ...

Novo Nordisk and Ascendis Pharma have partnered to develop therapies for metabolic and cardiovascular diseases, including a once-monthly GLP-1 receptor agonist that will initially target type 2 ...

Medscape Education is committed to disseminating the outcomes of the education programs through peer-reviewed publications and posters at leading medical conferences around the world. To this end, ...

Get ready for an exciting experience at AASLD 2024! The Medscape team is thrilled to be in San Diego from November 15-19 for this year’s AASLD conference, where we will bring you cutting-edge ...

Digital marketing serves as a critical component within a successful omnichannel strategy, guaranteeing seamless experiences for healthcare professionals and patients across various online platforms.

Johnson & Johnson (J&J) has announced that its pan-FGFR tyrosine kinase inhibitor Balversa (erdafitinib) has been granted marketing authorisation by the Medicines and Healthcare products Regulatory ...

Sometimes you just can’t see the wood from the trees. Teams gets so focussed on the technology or treatment you’re selling that the inevitable outcome is a feature-peddling monologue where you’re ...

Novo Nordisk has shared promising results from a late-stage study of semaglutide in patients with metabolic dysfunction-associated steatohepatitis (MASH), a progressive metabolic disease that affects ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved CStone Pharmaceuticals’ sugemalimab as part of a first-line combination treatment for lung cancer. The anti-PD-L1 monoclonal ...